血小板图血栓弹力图指导糖尿病下肢腔内血运重建术后血栓预防
前瞻性单中心序贯队列研究纳入164例≥60岁糖尿病下肢腔内血运重建患者,TEG-PM指导组62例依据术后系列检测调整抗血小板至预设抑制阈值30-86%,标准治疗组102例由术者决定。12个月靶血管血栓或临床显著狭窄TEG-PM组低于标准治疗组(9.7% vs. 25.5%,P=0.013),未校正HR 0.34(95%CI 0.14-0.84,P=0.019),多因素校正后HR 0.48(95%CI 0.19-1.24,P=0.131)不显著;大截肢、全因死亡、无截肢生存及临床相关非大出血无显著差异,无大出血发生。
要点
- TEG-PM指导组12个月靶血管血栓或临床显著狭窄发生率低于标准治疗组(9.7% vs. 25.5%)。
- 未校正风险降低显著(HR 0.34),多因素校正后关联减弱且不显著(HR 0.48)。
- 两组大截肢、死亡、无截肢生存及临床相关非大出血无显著差异,无大出血。
核心结论
- TEG-PM指导的血栓预防与糖尿病下肢腔内血运重建术后12个月靶血管血栓或临床显著狭窄发生率较低相关,且无大出血,但多因素校正后关联减弱。
研究设计与样本
- 前瞻性单中心序贯队列研究,纳入≥60岁因外周动脉疾病行下肢腔内血运重建的糖尿病患者164例。
- TEG-PM指导组62例依据术后系列TEG-PM检测调整抗血小板治疗以达到预设血小板抑制阈值30-86%。
- 标准治疗组102例术后血栓预防由术者决定。
主要发现
- 12个月靶血管血栓或临床显著狭窄TEG-PM组9.7%、标准治疗组25.5%(P=0.013)。
- 未校正HR 0.34(95%CI 0.14-0.84,P=0.019);多因素校正后HR 0.48(95%CI 0.19-1.24,P=0.131)。
- 12个月大截肢、全因死亡、无截肢生存及临床相关非大出血无显著差异。
- 无大出血发生。
关键数值与推荐
- TEG-PM指导组以血小板抑制阈值30-86%为目标调整抗血小板治疗。
- 主要结局为12个月靶血管血栓或临床显著狭窄。
临床怎么用
- 对糖尿病下肢腔内血运重建术后患者,可考虑用TEG-PM系列检测指导抗血小板调整以降低靶血管不良事件。
- 需注意多因素校正后获益不显著,TEG-PM指导策略的疗效尚需未来研究确认。
局限性
- 单中心序贯队列设计,非随机分组,可能存在选择偏倚。
- 多因素校正后主要结局关联不显著(HR 0.48,95%CI 0.19-1.24,P=0.131)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with diabetes represent one of the largest subgroups undergoing endovascular revascularization for peripheral artery disease (PAD) and remain at high risk for thrombosis and restenosis. Postprocedural antithrombotic management varies in practice and does not routinely measure platelet response. We evaluated whether thromboelastography with platelet mapping (TEG-PM)-guided thromboprophylaxis was associated with reduced target vessel thrombosis or clinically significant stenosis. METHODS: We performed a prospective, single-center, sequential cohort study of patients (≥60 years) with diabetes undergoing infrainguinal endovascular revascularization for PAD. In the standard of care (SOC) cohort, postoperative thromboprophylaxis was determined by the treating surgeon. In the TEG-PM-guided cohort, serial postoperative TEG-PM measurements informed antiplatelet adjustment to meet prespecified platelet inhibition thresholds (30-86%). The primary outcome was target vessel thrombosis or clinically significant stenosis at 12 months. RESULTS: Of 164 patients with diabetes, 62 received TEG-PM-guided thromboprophylaxis and 102 received SOC. At 12 months, target vessel thrombosis or clinically significant stenosis was lower with TEG-PM-guided therapy than SOC (9.7% vs. 25.5%; P = 0.013). TEG-PM-guided therapy was associated with lower unadjusted hazard of this outcome (hazard ratio [HR] 0.34; 95% confidence interval [CI] 0.14-0.84; P = 0.019), although this was not significant after adjustment (HR 0.48; 95% CI 0.19-1.24; P = 0.131). Major amputation, all-cause mortality, amputation-free survival, and clinically relevant nonmajor bleeding did not differ significantly at 12 months. No major bleeding occurred. CONCLUSION: TEG-PM-guided thromboprophylaxis was associated with a lower 12-month rate of target vessel thrombosis or clinically significant stenosis without major bleeding, although this association was attenuated after multivariable adjustment. Future studies should determine whether TEG-PM-guided antiplatelet therapy adjustment improves target vessel outcomes in patients with diabetes.
引用
- Patel SS, Fouzdar S, Bansal R, et al. Thromboelastography with Platelet Mapping-Guided Thromboprophylaxis in Patients with Diabetes Undergoing Infrainguinal Endovascular Revascularization. Ann Vasc Surg. 2026. PMID: 42697315. doi:10.1016/j.avsg.2026.08.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。